Assess the Safety and Efficacy of NKPL66 (CaPre™) in the Treatment of Mild-to-high Hypertriglyceridemia
Status:
Completed
Trial end date:
2013-09-01
Target enrollment:
Participant gender:
Summary
To evaluate the efficacy of 0.5, 1.0, 2.0 and 4.0 g/ day of CaPre™ in reducing fasting plasma
serum triglycerides over a four week period in patients with mild-to-high
hypertriglyceridemia as compared to the standard of care alone.